Nurix Therapeutics, Inc.NRIXNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-263.47M
↓ 152% below average
Average (7y)
$-104.52M
Historical baseline
Range
High:$-1.05M
Low:$-263.47M
CAGR
+34.4%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2025 | $-263.47M | -44.9% |
| 2024 | $-181.86M | -102.6% |
| 2023 | $-89.77M | +47.8% |
| 2022 | $-172.05M | -91.1% |
| 2021 | $-90.03M | -1843.1% |
| 2020 | $-4.63M | -341.2% |
| 2019 | $-1.05M | +96.8% |
| 2018 | $-33.27M | - |